Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

NCT01584648

Name: 5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma
Uploaded: 2021-04-13T00:00:00Z
Duration: 56 s

Sorry, no posts matched your criteria.

NCT01584648

Cookie settings